To study the safety and efficacy of four different doses of Wobenzym (an enzyme combination
consisting of pancreatin, papain, bromelain, trypsin, lipase, amylase, chymotrypsin, and
rutin) in patients with HIV infection whose CD4 count is between 250 and 400 cells/mm3. To
evaluate the effect of Wobenzym on certain surrogate markers associated with progression of
Patients must have:
HIV seropositivity with CD4 counts between 250 and 400 cells/mm3.
Patients with the following symptoms or conditions are excluded:
- Known hypersensitivity to hydrolytic enzymes such as Wobenzym.
- Known sensitivity to lactose.
- Presumption that the patient will not comply with the dosing schedule or follow-up
- Concurrent use of immunosuppressive therapy or steroids.